Carregando empresa
Just reported
From Generate Biomedicines's results release of 12 de novembro de 2026; its quarterly report has since been filed.
Actual
US$ 4,2M
-56% y/y
-33% q/q
Guided
—
No guide given
Actual
-US$ 0,68
Guided
—
No guide given
Actual
-US$ 91,5M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Generate Biomedicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$ 47,6BA+
EXELExelixis, Inc.US$ 16,8BA+
JAZZJazz Pharmaceuticals plcUS$ 15,5BA
TECHBIO-Techne CorpUS$ 11,4BA+
HALOHalozyme Therapeutics, Inc.US$ 11,4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 de out. de 2026CAGraded C, now AAs participações na receita são estimativas para six months ended June 30, 2026, não números de um relatório oficial.
GB-0895
An experimental antibody that blocks thymic stromal lymphopoietin, an immune-system signal. It is being tested in late-stage trials for severe asthma.
GB-4362
An experimental medicine designed to neutralize monomethyl auristatin E, a drug used in some cancer treatments. It has entered human testing.
GB-5267
An experimental cancer treatment using modified chimeric antigen receptor T cells, immune cells altered to recognize and attack cancer. It is being developed with Roswell Park Comprehensive Cancer Center.
Demonstrações financeiras completas →
Generate Biomedicines uses artificial intelligence and laboratory experiments to design and test proteins that could become medicines. Its most advanced candidate is being tested in severe asthma, and it is also developing treatments for other diseases. It has no medicines approved for sale; its current revenue comes from research collaborations with drug companies.
Construído a partir dos próprios documentos de Generate Biomedicines, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
Generate Biomedicines earns research payments from drug companies to design protein medicines, while developing its own experimental treatments for severe asthma and cancer.
Not rated
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Ainda não há histórico de notas para desenhar para Generate Biomedicines, Inc.. A nota trimestral é reconstruída apenas com os documentos que eram públicos na época, e esta empresa ainda não entregou o suficiente para pontuar um único trimestre.
